Tang Capital Acquisition Corp Files SPAC IPO on Nasdaq
Tang Capital Acquisition Corp, a special purpose acquisition company co-founded by a former Goldman Sachs Asia healthcare investment head, filed its S-1 registration statement with the SEC on October 6, 2026, to launch its Nasdaq IPO. It targets cross-border mergers with Chinese innovative drug and high-end medical device companies.
51CFO view：A CFO for such a SPAC must draft SEC S-1 ‘Management Discussion’ sections compliantly describing target selection criteria and build ASC 810-compliant pro forma financial statements for merger accounting. This demands acute SEC disclosure judgment and hands-on financial due diligence support for China-based healthcare targets.
Tang Capital Acquisition Corp, a special purpose acquisition company co-founded by a former Goldman Sachs Asia healthcare investment head, filed its S-1 registration statement with the SEC on October 6, 2026, to launch its Nasdaq IPO. It targets cross-border mergers with Chinese innovative drug and high-end medical device companies.
Source：SEC EDGAR · S-1 招股书备案